In recent news,
Astellas Pharma Inc. communicated multiple key developments. The US FDA acknowledged Astellas' resubmission of a biologics license application for
Zolbetuximab, setting a new action date. Both the European Commission and the National Medical Products Administration of China granted approvals for
PADCEV, another Astellas product, to treat advanced or metastatic urothelial Cancer. The FDA also granted approval for a new combination therapy for bladder cancer and other conditions. Astellas also completed the acquisition of
Propella Therapeutics and started a Phase 3 Clinical Study of Fezolinetant for VMS in Women with Breast Cancer. The company also announced the opening of new innovation centers in Massachusetts and South San Francisco. Lastly, they have entered into several research collaboration agreements, including partnerships with Yaskawa, Osaka University, and other institutions. On the downside, an Astellas' gastric cancer drug was declined by FDA, and there seems to be some legal friction around a patent suit for Myrbetriq.
Astellas Pharma Inc. News Analytics from Mon, 11 Oct 2021 07:00:00 GMT to Fri, 20 Sep 2024 13:17:00 GMT -
Rating 4
- Innovation 6
- Information 8
- Rumor -5
